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Tumour-associated neutrophils
and loss of epithelial PTEN
can promote corticosteroid-
insensitive MMP-9 expression
in the chronically inﬂamed
lung microenvironment
ABSTRACT
Matrix metalloproteinase-9 (MMP-9) is
increased in a number of pathological lung
conditions, where the proteinase contributes
to deleterious remodelling of the airways.
While both lung cancer and COPD are
associated with increased MMP-9 expression,
the cellular and molecular drivers of MMP-9
remain unresolved. In this study, MMP-9
transcript measured within the tumour region
from patients with non-small-cell lung cancer
(NSCLC) and coexisting COPD was found to
be uniformly increased relative to adjacent
tumour-free tissue. MMP-9 gene expression
and immunohistochemistry identiﬁed tumour-
associated neutrophils, but not macrophages,
as a predominant source of this proteinase. In
addition, PTEN gene expression was
signiﬁcantly reduced in tumour and there was
evidence of epithelial MMP-9 expression. To
explore whether PTEN can regulate epithelial
MMP-9 expression, a small interfering (si)RNA
knockdown strategy was used in Beas-2B
bronchial epithelial cells. PTEN knockdown by
siRNA selectively increased MMP-9 expression
in response to lipopolysaccharide in a
corticosteroid-insensitive manner. In summary,
tumour-associated neutrophils represent an
important source of MMP-9 in NSCLC, and
loss of epithelial PTEN may further augment
steroid-insensitive expression.
The global prevalence of lung cancer and
COPD will continue to rise, as smoking
consumption is yet to peak in developing
regions. Mutagens and free radicals in cig-
arette smoke damage and transform the
lung epithelium, leading to emergence of
a squamous metaplasia phenotype that
correlates with the severity of COPD.1 In
addition to mutagens in tobacco, shared
molecular drivers will contribute to the
emergence of lung cancer in people with
COPD.2 Chronic inﬂammation is a recog-
nised enabling characteristic in cancer,
where inﬂammatory and metaplastic cells
secrete a milieu of growth factors and
cytokines to drive remodelling processes.
This inﬂammatory environment can also
promote increased expression of proteases
that degrade extracellular matrix and
basement membrane, which is required
for migration of leucocytes and cancer
cells. One such proteinase known to be
elevated in COPD is matrix
metalloproteinase-9 (MMP-9), where neu-
trophils are an important source of
corticosteroid-resistant MMP-9 activity.3
In addition to leucocytes, the number of
basal epithelial cells positive for MMP-9
has been found to be elevated in COPD.4
MMP-9 is also known to be increased in
lung cancer, where it can play multiple
roles in tumour progression including
angiogenesis and establishment of a meta-
static niche. As in COPD, the cellular
source of MMP-9 is likely to be multifac-
torial in lung cancer including inﬂamma-
tory leucocytes and tumour cells of
epithelial origin. In this study, we show
that MMP-9 transcript expression is
increased in the tumour region relative
to the adjacent tumour-free region.
Figure 1A is a representative tissue section
of a tumour-free (ﬁgure 1A, top panel)
and intratumour (ﬁgure 1A, bottom panel)
region from a patient with COPD and his-
tologically conﬁrmed squamous cell car-
cinoma. MMP-9 transcript expression was
signiﬁcantly higher in the tumour sample
(ﬁgure 1B; mean±SEM 4.6±1.5-fold
increase, p<0.05) relative to the adjacent
control tissue (1.1±0.25-fold increase).
Stratiﬁcation by tumour histology revealed
no signiﬁcant difference between tumour
subtypes (ﬁgure 1C, adenocarcinoma 5.5
±2.4-fold increase vs squamous cell car-
cinoma 3.1±0.9-fold increase). The per-
centage area of positive staining for
CD68+ macrophages and MPO+ neutro-
phils revealed no signiﬁcant difference in
tissue accumulation of either leucocyte,
although there was a trend towards
increased numbers of tumour-associated
neutrophils (2.7±0.7% positive area) rela-
tive to adjacent control tissue (1.4±0.2%
positive area). Spearman correlation
revealed no association between MMP-9
expression and macrophage staining
(ﬁgure 1E, r=−0.42, p=0.23), whereas a
closer association between MMP-9 expres-
sion and tumour-associated neutrophils
was observed (ﬁgure 1F, r=0.63, p=0.05).
Consistent with this ﬁnding, immunohisto-
chemistry for MMP-9-positive cells using
serial tumour sections identiﬁed intensely
staining neutrophils in the tumour tissue
relative to weakly staining macrophages
(ﬁgure 1G). MMP-9 immunoreactivity in
cells of epithelial origin was also detected
in tumour sections (ﬁgure 1H).
Since tumour cells can also express
MMP-9 in NSCLC,5 we investigated
mechanisms by which cells of epithelial
origin could contribute to increased
MMP-9. In our analysed samples, PTEN
gene expression was 0.5±0.08-fold lower
in the tumour region (ﬁgure 2A,
#p<0.05). Consistent with MMP-9
expression, no signiﬁcant difference in
PTEN levels was observed between
NSCLC subtypes (ﬁgure 2B). Loss of
PTEN increases phosphoinositide-3-kinase
(PI3K)/Akt pathway activation in smokers
with dysplastic regions, suggesting that
PI3K activation is an early event in tumori-
genesis6 and PTEN was progressively
downregulated in COPD epithelium.7 To
investigate whether PTEN can contribute
to regulation of MMP-9 expression, siRNA
was used in bronchial epithelial Beas-2B
cells to reduce PTEN expression by 50–
70% (see online repository for methods
and additional data).
Control and PTEN knockdown (PTEN
KD) cells were stimulated with the bacter-
ial agonist lipopolysaccharide (LPS),
which increased interleukin-6 (IL-6) levels
approximately 20-fold (ﬁgure 2C) at
3 hours, with expression returning to
baseline by 48 hours (ﬁgure 2D). These
time points were chosen to represent the
peak (3 hours) and resolution (48 hours)
of inﬂammatory responses. No signiﬁcant
difference was observed between control
and PTEN KD cells. Budesonide signiﬁ-
cantly reduced peak LPS-induced IL-6
levels in control cells (ﬁgure 2C; 70%
reduction; analysis of variance (ANOVA),
*p<0.05 control cells LPS vs BUD-LPS).
Budesonide proved to be less effective in
reducing peak IL-6 levels in PTEN KD
cells (ﬁgure 2C; 54% reduction; p>0.05
PTEN KD cells LPS vs BUD-LPS). Since
mitogen-activated protein kinase (MAPK)
phosphatase-1 (MKP-1) contains consen-
sus glucocorticoid response elements in its
promoter, this gene was measured as a
control for steroid exposure. Budesonide-
induced levels of MKP-1 were not altered
in PTEN KD cells at 3 hours, hence
steroid receptor engagement and nuclear
translocation is maintained (ﬁgure 2E).
Preliminary assessment of MMP-9
expression at 3 hours demonstrated no
increase in MMP-9 levels in either control
or PTEN KD cells (data not shown). At
the later 48 hour time point, LPS stimula-
tion of control cells did not signiﬁcantly
alter baseline MMP-9 expression. In con-
trast, PTEN KD cells responded to LPS by
increasing MMP-9 expression (ﬁgure 2F;
4.7±0.5-fold increase; two-way ANOVA
#p<0.05, control vs PTEN KD cells).
LPS-induced expression of MMP-9 was
not inhibited by budesonide in PTEN KD
cells (ﬁgure 2F; 4.7±0.8-fold increase;
BUD-LPS treated control vs PTEN KD
cells, two-way ANOVA #p<0.05). The
promoter region of human MMP-9 con-
tains binding sites for multiple transcrip-
tion factors. We have previously shown
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that the activator protein-1 (AP-1) was
markedly increased in LPS-stimulated
Beas-2B cells;8 hence AP-1 requires syner-
gistic cooperation with multiple transcrip-
tion factors to stimulate MMP-9
expression. IL-6 interacts with glycopro-
tein 130 and activates the JAK/Stat
pathway. PTEN is an important negative
regulator of Stat3, and functional cooper-
ation of the Stat3 and AP-1 transcription
factors plays a crucial role in transcription
of the MMP-9 gene through engagement
of juxtaposed promoter elements.9 Hence,
loss of PTEN may result in enhanced
Stat3–AP-1 interactions to sustain MMP-9
expression.
In summary, tumour-associated neutro-
phils in NSCLC were most strongly asso-
ciated with MMP-9 expression in our
study. Neutrophils can be transformed by
the malignant microenvironment, leading
to divergent phenotypes that release
proangiogenic factors such as MMP-9.10
We also propose that reduced expression
Figure 1 Matrix metalloproteinase-9 (MMP-9) transcript is increased in the tumour region in patients with COPD. (A) Representative H&E-stained
tissue section from formaldehyde-ﬁxed parafﬁn-embedded blocks of tissue from the tumour site (bottom panel) and the adjacent parenchyma that
was histologically free of tumour (top panel). (B) MMP-9 levels were expressed as fold change relative to individual adjacent control sample (n=10;
#Wilcoxon signed rank test, p<0.05). (C) Levels of MMP-9 grouped on the basis of non-small-cell lung cancer tumour subtype showed no difference
in expression. ADENO, adenocarcinoma; SQUAM, squamous cell carcinoma. (D) Representative immunostain of tumour sections for CD68 (top panel)
and MPO (bottom panel). (E) Spearman correlation demonstrates no association between CD68+ macrophages and MMP-9 expression, whereas
(F) MPO+ neutrophils demonstrated a closer relationship with MMP-9 in tumour sections. (G) Representative tumour section stained for MMP-9
identiﬁed intense immunoreactivity in tumour-associated neutrophils (open arrows), but not macrophages (black arrows). (H) There was also
evidence of MMP-9 immunoreactivity in cells of epithelial origin.
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of epithelial PTEN may activate an
alternative transcriptional network to
stimulate steroid-insensitive epithelial
expression of MMP-9. Hence, novel
strategies aimed at reducing tumour-
associated neutrophils and restoring epi-
thelial PTEN expression should be
considered.
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